公开(公告)号：US12090301B2

公开(公告)日：2024-09-17

申请号：US16404456

申请日：2019-05-06

Applicant: Insulet Corporation

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Yibin Zheng ,  Thomas Arnold Peyser ,  Jennifer Lena Schneider

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/14244 ,  A61M5/145 ,  A61B5/486 ,  A61B5/6832 ,  A61M2005/14208 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US11986630B2

公开(公告)日：2024-05-21

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor ,  Trang Ly ,  Yibin Zheng ,  Connor Gullifer ,  Kyle Grover

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US11833329B2

公开(公告)日：2023-12-05

申请号：US17123369

申请日：2020-12-16

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2005/14208 ,  A61M2205/3303 ,  A61M2205/3569 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.

公开(公告)号：US12036389B2

公开(公告)日：2024-07-16

申请号：US17142425

申请日：2021-01-06

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2230/201

Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on a history of glucose values and insulin deliveries for a user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal event or the exercise event by the user.

公开(公告)号：US11439754B1

公开(公告)日：2022-09-13

申请号：US17539270

申请日：2021-12-01

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.

公开(公告)号：US12226612B2

公开(公告)日：2025-02-18

申请号：US17715589

申请日：2022-04-07

Applicant: INSULET CORPORATION

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US11911596B2

公开(公告)日：2024-02-27

申请号：US18186539

申请日：2023-03-20

Applicant: INSULET CORPORATION

Inventor： Joon Bok Lee ,  Mengdi Li ,  Jason O'Connor ,  Yibin Zheng

IPC: G08B1/08 ,  A61M5/172 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  H04L67/141

CPC classification number: A61M5/1723 ,  G16H10/40 ,  G16H10/60 ,  G16H20/17 ,  G16H40/60 ,  G16H40/67 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61M2202/07 ,  A61M2205/3584 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2230/20 ,  A61M2230/201 ,  H04L67/141

Abstract: Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.

公开(公告)号：US11904140B2

公开(公告)日：2024-02-20

申请号：US17330115

申请日：2021-05-25

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Trang Ly

IPC: A61M5/172 ,  G16H20/17 ,  A61B5/145 ,  A61B5/00 ,  A61M5/142 ,  G06Q30/0283

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17 ,  A61M2005/14208 ,  A61M2205/52 ,  A61M2230/201

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US11628251B2

公开(公告)日：2023-04-18

申请号：US16586440

申请日：2019-09-27

Applicant: INSULET CORPORATION

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Todd Vienneau ,  Yibin Zheng ,  Ashutosh Zade

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US11547800B2

公开(公告)日：2023-01-10

申请号：US16789051

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor

IPC: A61M5/172 ,  A61K38/28 ,  A61M31/00 ,  G16H40/63 ,  A61M5/142

Abstract: Exemplary embodiments described herein relate to a closed loop artificial pancreas system. The artificial pancreas system seeks to automatically and continuously control the blood glucose level of a user by emulating the endocrine functionality of a healthy pancreas. The artificial pancreas system uses a closed loop control system with a cost function. The penalty function helps to bound the infusion rate of insulin to attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use a generic or baseline parameter for a user's insulin needs in a cost function, the exemplary embodiments may use a customized parameter in the cost function that reflects the individualized insulin needs of the user. The use of the customized parameter causes the cost function to result in insulin dosages over time better suited to the individualized insulin needs of the user. This helps to better avoid hypoglycemia and hyperglycemia.